Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
April 23, 2025
Earnings Call Speaker Segments
James Bushnell
executiveHello, and thanks for being here. We put out a press release earlier today with full details about our results for the first quarter of 2025. You can find that release on our site, pmi.com. I'll walk through the terminology, which covers how we define smoke-free products, along with adjustments, other calculations, and reconciliations to the most directly comparable U.S. GAAP measures for the non-GAAP financial measures mentioned in this presentation — all of that appears in Exhibit 99.2 of the company's Form 8-K dated April 23, 2025, and also on our Investor Relations website. Remarks today include forward-looking statements and projections of future results. Please see the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. Emmanuel Babeau, Chief Financial Officer, is with me today. Emmanuel, the floor is yours.
Emmanuel Babeau
executiveThanks, James, and good morning to all of you. During the first quarter, we got the year off to a powerful beginning, with every major component of the business pitching in meaningfully to produce double-digit gains in organic net revenue, operating income, and adjusted diluted EPS, measured both in constant currency and in dollar terms. Our smoke-free segment turned in outstanding results everywhere, as shipment volumes climbed 14.4% versus a year earlier, organic net revenue rose 20%, and organic gross profit surged 33%, since gross margin widened across all 3 smoke-free categories. The main drivers were ZYN's swift expansion along with IQOS's ongoing volume momentum, operating leverage, and scale benefits. Smoke-free products now represent 44% of total gross profit, as we keep rolling out our multi-category strategy in various markets and widening our avenues for growth. IQOS posted HTU adjusted IMS growth of nearly 10%, sustaining solid results in Japan as well as Europe, even with the annualization effect of the EU characterizing flavor ban. For the remainder of the year, we anticipate double-digit growth. Once again, ZYN came through with robust U.S. growth; shipments rose an impressive 53% to hit 202 million cans, surpassing what we had initially expected, because demand stayed elevated and production capacity came online sooner than planned in the latter part of March, which permitted some initial restocking of trade inventories. Can volumes for international nicotine pouches likewise rose 53%, or 182% when the Nordics are excluded, which shows how dynamic this emerging category is worldwide; in e-vapor, ZYN's Q1 performance was impressive, showing its growing contribution within our multi-category lineup. Shipments more than doubled from a year earlier and gross margin widened further, powered by robust pod growth in Europe as we broadened our distribution and commercial efforts. In combustibles, higher overall volumes, together with solid pricing and continuing cost programs, produced a strong result even though geographic mix was notably negative because of greater volumes in lower-margin markets. All told, the very robust and ever more profitable underlying expansion of our smoke-free business combined with very solid combustible results and the extra boost from favorable shipment timing; that let us generate 16% organic operating income growth and 250 basis points of adjusted OI margin expansion, bringing it to 40.7%, and it yielded strong double-digit adjusted diluted EPS growth in both currency-neutral and dollar terms in spite of currency headwinds. Although the year is still young and considerable uncertainty surrounds the global economic outlook, we stay confident that we will secure yet another year of superior growth. Accordingly, we now project double-digit adjusted diluted EPS growth at prevailing exchange rates. Now for the headline figures. We achieved volume growth of 3.9%, which mirrors the tremendous dynamism of our smoke-free business. Along with solid pricing and notwithstanding unfavorable combustible mix, we generated double-digit organic net revenue growth of 10.2%, amounting to $9.3 billion in total. Additionally, our commercial model shift in Indonesia for the below Tier 1 cigarette segment, where we now serve as a handling agent, created a technical impact. Net revenue and cost of goods sold are lower because of this, yet gross profit and operating income see no meaningful effect. If you set aside this impact, which will significantly influence the first 3 quarters of the year, organic net revenues rose by roughly plus 12%; and as I noted, our smoke-free business served as the main engine behind organic adjusted OI growth of plus 16%, or plus 12.8% when measured in dollar terms. Q1 adjusted diluted EPS rose plus 17.3% in constant currency and plus 12.7% in dollar terms, reaching $1.69. A $0.07 unfavorable currency variance is included here, largely from nonrecurring transactional losses during the quarter tied to currency volatility. The topline and gross margin results of our smoke-free business were the main reason for this stronger than expected performance. Great work by our manufacturing team in speeding up capacity initiatives gave an extra boost to excellent ZYN performance. Robust European performance and roughly 1 billion units of favorable shipment timing, which we anticipate reversing in H2, were part of strong IQOS HTU shipment growth. The resilience of our combustible business complemented this. Let's examine category performance more closely. Net revenue for our smoke-free business climbed plus 20.4%, and gross profit climbed plus 33.1%. Organic gross margin expansion of an impressive plus 670 basis points to surpass 70% resulted from this, more than 5 points above combustible's gross margin at the current category and geographic mix of SSPs. As I noted, this mirrors an acceleration in gross margin expansion across all 3 smoke-free categories, particularly when combined with the positive mix impact from ZYN's accretive unit economics and pricing on both HTUs and ZYN. Very strong IQOS gross margin expansion mirrors the powerful growth and scale effect of this large and growing business, manufacturing productivities and a comparison benefit from higher device shipments in the prior year when ILUMA I was launched in Japan. On an organic basis, combustible net revenues and gross profit rose plus 3.8% and plus 5.3%, respectively. Pricing was strong and volume was positive, yet a notably negative geographic mix appeared this quarter because of growth in markets such as Turkey and Egypt, plus the technical impact from Indonesia. We anticipate both pricing and negative geographic mix to moderate across the remainder of the year and aim for combustible gross margin expansion organically and in dollar terms. As expected, input cost headwinds became less severe relative to recent years, and under current assumptions, we anticipate further improvement in 2026. Let's look more closely at our volumes. Shipment growth of plus 3.9% came mainly from our smoke-free business, with every category contributing positively and keeping us on track for a fifth consecutive year of total volume growth. Sales of smoke-free items rose 14.4%, surpassing the full-year guidance band of 12% to 14%, driven by really strong performance from IQOS, ZYN and VEEV. Beyond those 3 brands expanding, which I discussed previously, I should note that our legacy smoke-free operations encompass U.S. moist snuff and Scandinavian snus, both of which saw a slight dip during the quarter. Even so, shipments of oral smoke-free products picked up pace compared with the previous quarter, reaching 27% growth. Cigarette shipment volumes turned in a fourth straight quarter of gains, as we captured share in an industry that shrank slightly, helped by ongoing expansion in countries where smoke-free options remain banned, like Turkey and India. You've recently heard us discuss our multi-category approach to smoke-free products, using the strength of the IQOS brand along with commercial infrastructure across international markets to speed up additional growth from ZYN and VEEV. That's borne out by our robust smoke-free portfolio performance in Q1, with clear accretion by region and by market. We now have 46 markets offering more than one smoke-free product, among them 16 where all 3 PMI categories are available. Carrying out this 3-pronged strategy is delivering favorable outcomes in markets including the Czech Republic, Romania, Switzerland and our Global Travel Retail operation, plus encouraging early progress in the U.K. and Italy. It's also reinforcing our standing as a worldwide leader in smoke-free products.
Emmanuel Babeau
executiveFor the first quarter, organic net revenue increased by double digits once more, and all 3 pillars of the structural growth model we follow — volume, price, and smoke-free mix — powered that result. On pricing, we added 6 points, which came from combustible pricing above 8% and roughly 3% for smoke-free when devices are excluded. Shifting toward smoke-free products, U.S. smoke-free mix included, added another 3.1 points of favorable mix. On the other side, combustible geographic mix and other items subtracted 2.7 points; that drag was larger than in earlier quarters because of the technical Indonesia effect and the combustible market mix dynamics I walked through previously. Currency cost us 3.9 points, and acquisition and divestiture took off another 0.5 points, with the Vectura divestment inside that figure. Now on to gross margin. Organically we expanded it by a very robust 240 basis points, and by plus 360 basis points once currency, acquisitions and divestitures are included. Within that, pricing added plus 180 basis points, which more than covered an 80 basis point hit from cost inflation after netting productivities and other cost items. Smoke-free growth contributed an outstanding plus 230 basis points, while combustible ex-pricing was flat, Indonesia impact included. The strong gross margin figure drove a 250 basis point increase in adjusted operating income margin. On an organic basis, after accounting for currency effects in our cost base, the Vectura sale, and other scope impacts, that gain was 200 basis points. Even with a 140 basis point hit from rising SG&A expenses, we still delivered this notable margin improvement. Those higher SG&A costs stemmed from continued spending on smoke-free expansion, including investments in the U.S., a weak comparison from the prior year, and how our 2025 investment is timed. Because we remain committed to funding topline growth, we aim for organic SG&A growth this year to be approximately in line with net revenue growth. Our attention continues to be on how efficiently we run our factories and administrative operations, and during the first quarter we achieved gross cost reductions exceeding $180 million, split between cost of goods sold and SG&A. After generating more than $750 million in savings during 2024, we have a solid position to reach the $2 billion goal spanning 2024 through 2026. Now, regarding IQOS: the way the calendar fell and the fact that a full year has passed since the EU flavor ban took effect both held back adjusted IMS in Q1, just as we expected. Despite that, a gain of 9.4% under these circumstances indicates the underlying momentum remains strong; looking ahead to the remainder of the year, we expect double-digit growth, which lines up with our target of 10% to 12%. Supporting that effort are commercial programs focused on brand development, plus continuous device and consumable innovation, as ILUMA i gets introduced in stages alongside additional consumable options under TEREA, LEVIA and DELIA. Looking further ahead, a substantial IQOS innovation pipeline exists that will continue enhancing both the range and the caliber of what users get from this iconic brand. According to our latest integrated report, over 99% of the adjusted R&D expenditure in 2024 was directed to smoke-free products, consistent with our activity during the preceding 4 years as we continue advancing consumer centered product development. Moving on to Europe, the strong performance of our IQOS business is helping us create an integrated portfolio across multiple categories, which accelerates the pace at which consumers switch and value is generated. In Q1, total shipments for our leading smoke-free brand increased 17.5%, with ZYN and VEEV both contributing more. Shipments of IQOS HTUs climbed over 15%, a figure that benefits from a favorable prior-year comparison. Our spending on brand-building efforts can be seen in the new partnership with SELETTI, a well-known Italian designer, at Milan Design Week, which is part of the IQOS Curious X campaign. Turning to IQOS: our adjusted IMS for HTUs in the first quarter rose 7.4%, lifting our combined cigarette and HTU share to an all-time high of 11.4%. Across the region, adjusted IMS posted double-digit gains in numerous markets, with Spain, Germany, Bulgaria and Greece each growing in the high teens or better. Those gains were enough to overcome annualization effects, which, as we noted three months ago, weighed most heavily in Q1, particularly in Italy. I'm especially encouraged that our sequential share in Italy remains solid, reaching a Q1 record of 18.4%, rising steadily as the quarter went on. Overall, adjusted IMS growth in Q1 for the region matched what we had expected, and we're looking for another strong quarter in Q2, followed by a pickup in the back half of the year. When it comes to how the flavor ban affects us, our read hasn't changed — after implementation, we generally see markets recover in a fairly similar way. For 2025, we continue to anticipate a hit of roughly 1 billion units, largely because of annualization, and this year only Hungary and Slovakia have put the ban in place so far. Poland stands out as the key market to watch, where the future debt is set to arrive in early 2026. On top of that, we keep introducing new and improved versions of LEVIA, our tobacco-free consumable, and the results so far look promising. Take Hungary as a clear example: there, LEVIA captured a double-digit portion of < > HTU within under three months of hitting the market. Steady expansion in < > shows how far we've come across the region, and that story includes Hungary too, where Budapest's share climbed to nearly 42% — more than four points above < >. What's striking is that IQOS has now crossed the 10% < > 30% threshold in 24 out of the 34 European markets where it's available. Among the notable launches regionwide are London, Greece, Zurich, Lisbon and < >. How regulation takes shape plays a decisive part in how quickly smoke-free products advance, and we take heart from encouraging moves lately in several markets that have acknowledged tobacco harm reduction's place within their policy frameworks. That covers Greece, where a specialized sign-up system was launched to back the time-based approach for smoke-free offerings. It also covers Hungary, where factor and client-based messaging to consumers about smoke-free products is permitted, in contrast to the outright advertising prohibition that applies to combustible ones. In Ukraine, I'm delighted that HTU versus cigarettes was introduced following a stretch of < >; over in Japan, adjusted HTU IMS growth for us reached plus 9.3%, which effectively represents a 10th quarter of double-digit growth when the lease year is taken into account. Measured year on year, HTU adjusted share climbed 3 percentage points, and on a sequential basis it gained 1.6 points, finishing at 32.3%, which underscores even further how dynamic the innovation behind the innovative IQOS brand and product portfolio is in this key market. IQOS heated tobacco units accounted for over three-quarters of category growth during the first quarter. Add in our cigarette operations, and PMI is now the volume leader in this space, with 75% from our HTU. The broader smoke-free segment continues to expand, reaching nearly 48% on a national offset basis in March, as 13 cities and 8 < > approach the 50% portfolio threshold. Globally, IQOS keeps delivering very strong results, as < > shows. Notable points include remarkable year-over-year gains in Indonesia's capital and Mexico, < > 5% share, solid momentum throughout the Middle East and North Africa, and robust growth in Belgrade at 17.7% share notwithstanding heightened positive activity. Over in South Korea, IQOS reached a fresh peak, capturing a 14.1% share in Peru, helped along by the ILUMA i rollout in a market where competition runs high. Overall share results in Peru continue to feel pressure from expansion in the combustible category, where rival supply has returned to normal.
Emmanuel Babeau
executiveOne more thing I'd like to highlight is the way our global travel retail business has expanded via third-party channels — that's an essential element of our category-wide proposition. We recorded strong HTU growth across the board, holding a share above 18% in airports that carry IQOS. In the US, exactly as planned, we started selling IQOS 3 devices and HTUs directly in < > at the end of March, following several months of dedicated engagement with legal-age consumers. While intentionally limited in scale, the uptake has been subdued, and we have additional IQOS 3 initiatives scheduled in the coming months as we prepare for the < > launch of IQOS ILUMA. Bear in mind, we aren't banking on significant HTU volumes from America in our full-year < >. Now to ZYN — it continues to resonate strongly with adult nicotine users as a premium-equity, superior product, and it's producing excellent results. Persistent strong demand along with additional manufacturing capacity enabled us to ship 53% more, exceeding 200 million cans in the quarter; that extra 70 million compared with a year ago is significant. One thing to note: last year's first quarter involved retailer and distributor inventories being reduced repeatedly, so volumes ran unusually high relative to shipments, and this quarter saw the beginning of < >. As we continue increasing production at our own plant, we accelerated one facility's debt this quarter into late March. That allowed us to ship more at the very end of the quarter and pulled forward some initial distributor < >. Because only a small fraction of those additional shipments made it to retail during the quarter, in-store availability hasn't truly been impacted yet; we're targeting supply fully normalized in Q3 of this year. ZYN's performance stays quite strong where it is actually sold, under the circumstances, with double-digit < > growth that's robust. Per < >, Q1 offset volume climbed about 15% compared with a year earlier, and statutory value share remained solid above 70% even while rivals discounted aggressively. Although < > data derives from only a small panel of stores, it similarly shows our offset volume sales were held back by availability, declining 1.5% quarter over quarter to 51.5%. We've already observed our share in MSA data — which follows shipments from distributor to retail — recover to almost 66% in March thanks to that limited flow-through I referenced. With the category expanding around < >, we led in supply as intended, and we anticipate ZYN's impact to grow steadily in the months ahead as in-store availability improves and we resume commercial and marketing activity. We remain excited about this dynamic category's growth prospects and its capacity to shift legal-age consumers away from cigarettes and other traditional tobacco products. ZYN is still the only new nicotine pouch product the FDA has cleared, covering all variants in both < > in America. There's a substantial market we can address — millions of people of legal age throughout the United States — and our goal is to go past the customers we currently serve and get other legal-age individuals involved more actively. When it comes to ZYN, demand that hasn't yet shown up is robust, and our capacity is growing more quickly than we had planned. Our guidance for shipments has been raised to a range of 800 million to 840 million cans for the year. Because of the outstanding efforts of our team in the field, we continue to work on adding capacity at our plant. Our second manufacturing location in the U.S., which is in Colorado, is coming along nicely, and production there is set to start in early 2026. We have not stepped back from our dedication to investing in American manufacturing. The large amounts we have put into the U.S. ought to keep generating results via substantial job creation and economic gains for the country. Now shifting to outside America: we continue to grow ZYN, leveraging our IQOS and ZYN presence to create awareness and trial among legal-age individuals. In just about every market, the overall international category is still latent, and spending is about the same magnitude as the U.S. when it comes to volume growth. After Q1 launches in the UAE and Colombia, we now have operations in 38 markets around the world, and as you can see, at minimum the whole addressable market presents a meaningful opportunity given the unit economics. Our volume actually increased by over 53%, with shipments almost doubling outside the Nordics, including gaining momentum in European markets such as Austria, Switzerland and the U.K., where we started the national account rollout. In emerging markets, Pakistan, Mexico and South Africa all kept demonstrating strong progress. One notable standout is CMI Global Travel Retail, which additionally enhances global visibility and awareness of ZYN within our offering. Lastly, let me wrap up our smoke-free performance. As our volumes and gross margin increase, ZYN is growing more important. On an equivalent unit basis, shipment volume hit 0.6 billion, double what it was a year earlier, driven by strong results in Europe, where the cost segment keeps expanding rapidly, partly because disposable faces more bans and restrictions. In key markets, B1 adoption rose while abandonment stayed low, reflecting the quality and presentation of this premium product and what it can deliver. Now to combustible. Our Q1 performance was solid, with organic net revenue up 3.8%, or closer to 7% once you exclude the Indonesia technical impact. The main factor here was solid pricing, which came in at plus 8.3%, and we saw meaningful contributions from Turkey, Poland and Germany, along with a less favorable timing dynamic. Our expectation for the full year on combustible pricing stays at plus 5% to plus 6%. Cigarette industry volume fell 1.3% during Q1, which happened because of expansion in geographies where smoke-free products are latent or not present, and that was more than offset by accelerated CR declines. Additionally, we delivered very strong expansion of 340 basis points on an organic basis. In places like Turkey and India, smoke-free products still aren't broadly on the market, so we anticipate that shortfall will continue, though demographic trends give us some lift in certain geographies. Even so, for the full year we still forecast a decline in the low single digits. Category share did well, climbing 0.4 points in Q1, and both Marlboro and our global brand portfolio hit all-time highs. Looking ahead, we continue to target steady category share growth, and our key priorities are maximizing value while supporting smoke-free product expansion. On top of all that, combustible organic profit continued rising sharply, up 5.3%, following the 2024 recovery. That momentum feeds into our 2025 outlook; we had a very strong first quarter, aided by margin that came in above expectations, and we remain confident about delivering another year of profitable growth. We delivered very strong expansion of 340 basis points on an organic basis. So we're restating the currency-neutral growth guidance we issued in February, even as uncertainty grows in the global macroeconomic environment. As a company operating worldwide, we've extended our adoption widely throughout the global supplier network, and with an established U.S. footprint, we believe we're positioned well to offset some cost-related pressures. While conditions stay volatile, we currently don't anticipate any material impact on our operations from tariffs recently imposed or withdrawn. We expect the strong momentum in our smoke-free business to continue, supported by the benefits of rolling out more multi-category offerings. As I noted, we're raising our forecast for U.S. shipments to between 800 million and 840 million cans.
Emmanuel Babeau
executiveThis reinforces what we're projecting for SFP shipment growth — an increase between 12% and 14% — and that figure bakes in a growth assumption for IQOS. On top of that, our expectation remains that PMI's total organic net revenue will rise within the plus range, organic operating income will also grow, and currency neutral adjusted diluted growth will come in between 10.5% and 12.5%. As we said in this morning's press release, our 2025 adjusted diluted EPS forecast is being lifted from $7.36 to $7.49. That translates into growth of 12% to 14% measured in dollar terms, and it accounts for a favorable estimated currency impact of $0.10 at prevailing expense rate. The main factors here are the recent strengthening we've seen in the euro, the Japanese yen and the Russian ruble, though a firmer currency is canceling out some of that. For HTU shipment volume, we're assuming a range of 37.5 billion to 38.5 billion, and we expect HTU adjusted IMS growth to stay strong again this quarter at roughly 10%. As for U.S. ZYN, we're expecting Q1 shipments to come in around where they were previously, given that the trade restructuring is still in progress and offtake is recovering at a gradual pace. On adjusted diluted EPS, we're projecting between $1.80 and $1.85, and that figure includes a $0.06 benefit from currency swings assuming current growth trends. We expect a solid first half overall, with organic net revenue growth landing close to the upper bound of our full-year target range, and organic growth coming in slightly higher than that. As for the balance sheet, paying down debt remains a leading priority, and we're still aiming for further reduction in 2025, keeping us on course to hit a ratio of roughly 2x by the close of 2026. We think the growth trajectory we have stacks up better than any other big consumer company, which is what our three-year CAGR objective reflects, and we're making solid progress toward hitting it — growing quality or adjusted diluted EPS in dollar terms ranks among our main focus areas, and 2024 proved we'll act decisively to handle possible currency swings, hedging being one tool we use. Alongside hitting that growth number, we've put in massive work over the past three years to shore up our business, and we keep pushing toward our goal of becoming far more disciplined. This quarter lines up with the release of our annual integrated report, which offers an in-depth look at how the company has performed on both financial and nonfinancial measures. Among the highlights are the significant steps and initiatives we're pursuing around use access prevention, along with the gains we've achieved in operational efficiency, in making our business more resilient, in pushing innovation forward, and ultimately in the business itself. As I noted in the report, our work in sustainability is driven first and foremost by business considerations, aimed at both customizing and boosting the growth of our portfolio transformation so that we keep creating value. I'd urge anyone curious about how and why we are transforming already to take a look. To wrap up today's presentation, I'd like to leave you with a few main takeaways. After a great beginning to the year, we're now positioned for yet another year of robust results in '25. Macroeconomic fluctuations can impact any company, but we believe we're well positioned to manage external pressures. We have three powerful drivers of growth, and each one can set prices, plus we have strong smoke-free categories along with growing volumes — and in that area, we're targeting a fifth consecutive year of expansion, fueled by IQOS, ZYN and VEEV. Since we keep putting substantial money behind our smoke-free labels, these engines likewise add to profit, and paired with our forward-leaning steps on price and expense, we feel very confident about lasting adjusted diluted EPS increases in currency neutral terms and < >. Last, we stay a business that generates more, with steadfast dedication to our ever-improving dividend approach; we anticipate giving shareholders even more returns as our transformation brings about durable growth. Thanks, and at this point we're delighted to take your questions.
Bonnie Herzog
analystI have a handful of things to ask about ZYN. Would you be able to share a bit more detail regarding the out-of-stock problems that may still be affecting you in the U.S.? I realize you mentioned this already, but I'm also wondering how much time you believe retailers will need before their inventories are back to normal. And I realize you lifted your shipment outlook for ZYN for this year, yet it still suggests growth will slow down versus last year to roughly, I believe, 35% for the remainder of the year; that sits at the bottom of your range compared with, I suppose, the 53% you posted this quarter. So I'm just hoping you could walk us through the rationale here, perhaps just the phasing.
Emmanuel Babeau
executiveAbsolutely, Bonnie. Glad to do so. Naturally, 2025 is a distinctive year for us with ZYN in the U.S., since it will combine continued robust expansion with powerful consumer offtake growth. Naturally, regarding the shipment figures, do be careful, and I pointed this out during my remarks, since a year ago we obviously saw consumer offtake in Q1 that was far, far more robust than our shipment. That was when consumers began clearing the shelves; so caution is warranted when examining the shipment numbers to see whether they now mirror consumer offtake and to factor that in; and alongside this robust growth we anticipate from consumer offtake; and we have a highly dynamic category, expanding 30% to 35%, even though the leader ZYN was constrained, we will layer on top of that this replenishment, this restocking. I won't speculate on what exactly that amounts to, but it is definitely a few tens of million cans; and we have begun, thanks to this solid production performance I described, sending more product to, first of all, wholesalers, distributors and themselves, they will begin shipping to retailers; so it will be a very gradual process. There remain, naturally, quite, I would say, significant instances of out of stock; we will keep up the replenishment in the second quarter, possibly part of the third quarter too, and we've been explaining that we explained — we anticipate returning to a normalized situation, if I may put it that way. Consequently, no further material out-of-stock situation in the third quarter of '25; so regarding shipment, that will be the profile across the year of an accelerating growth for our shipments. That is our expectation, which will mirror, first, the consumer effect that will accelerate. And then, naturally, the effect of restocking is going to diminish as we complete that restocking, so to speak. So it's a specific pattern, and the restocking, in a way, is partly going to mask the reality that consumer offtake is growing, which we will see over the course of the year.
Bonnie Herzog
analystThat's useful, and I appreciate it. Then let me ask a second thing about margins. During the quarter, you achieved strong margin expansion. So for the rest of the year, how should we view what will keep driving that expansion? I suppose particularly given what you brought up regarding SG&A continuing to grow along with the investments, and so on. And building on that, I realize we've discussed this previously, but how should we also consider the margin gap that exists today between your combustible business and smoke-free products, and then perhaps the main drivers that would widen that gap further across the next couple of years?
Emmanuel Babeau
executiveLook, Bonnie, clearly, we're quite happy with the expansion in our margin. That's a target of ours for '25, and our expectation is something we feel very positive about. In Q1 we have a clear demonstration of how strongly we performed when it comes to margin expansion. First and foremost, it is obviously our smoke-free products that are driving this margin expansion. For our smoke-free business in Q1, you have an organic expansion of an impressive 670 basis points. Don't use that as a benchmark for the whole year, but it does mean we're now above a 70% gross margin rate in the smoke-free business. Versus combustible, that's 5 percentage points higher. So since our smoke-free business is growing, of course, very rapidly and more quickly than combustible, it means at the margin level we benefit from a mix evolution that is very positive. And between smoke-free and combustible, we believe the difference should remain through '25. I'm not saying it will remain at exactly the same level, but a very material difference between the 2 is something we're going to keep, and from this positive mix effect we're going to keep benefiting. For the future, I think there are a number of drivers that will keep playing on the margin for our smoke-free portfolio. There's a mix that comes from ZYN. In the U.S., ZYN has the best-in-class gross profit margin. So a positive impact comes when we grow fast in the U.S. You have all the scale impact on cost that we're generating. And over the last 2 to 3 years, if you look, you've seen margin on IQOS improve gradually on a very consistent basis. In the first quarter this is certainly magnified, because we have fewer device sales. We had big device sales last year in Japan as ILUMA i was being launched. So that helps the margin. But fundamentally, from scale impact, productivity and better device performance, we're benefiting. And then there's some pricing, which for our smoke-free business we've seen at 3% on consumable. So price is something we're raising as well. And the last element, which today is more marginal, is that on VEEV we're also improving margin, so that helps too. So as you can see, behind our smoke-free business there are many positive drivers, and for margin improvement, the smoke-free business is the driver for — or the first driver for it.
Matt Smith
analystSince the first quarter was so strong and we now have a clearer view of the second, let's start with the guidance picture. Looking at constant currency, first half EPS growth is a few points above the upper limit of your full year outlook. Can you explain what's going on in the second half that we should bear in mind? My math suggests the implied constant currency EPS growth for that stretch lands a couple of links below the full year average — is it just the general shape of the year?
Emmanuel Babeau
executiveSure, Matt. Happy to take that. So what we're signaling is that on revenue growth, we expect to be comfortably inside the total range for the year; on OI, we expect to finish a bit higher. Those are the normal swings you see through the year, with H1 and H2 differing — there could be some comparison basis involved, and possibly some phasing in how we decide to place SG&A. So in this case, I wouldn't read anything as a change in the fundamental business when you set H1 against H2. It's really about how a range of factors are timed for shipment across the year and for investments, though I'd say we expect a strong year as the quarters unfold. And we've been pointing out, for instance, that in certain areas we expect an acceleration for IQOS in the second half on IMS — but that won't automatically show up in shipment, because shipment phasing can be different. So again, I think we expect solid momentum all year for our smoke-free portfolio. We've been pointing out that in combustible, we had positive volume in Q1, but for the full year, we expect a low single-digit decline. That implies the later part of the year will bring more negative volume for combustible. Even so, we definitely expect strength across the year. Now, looking at the sequential trend, it declined by 1.45 points to 61.5%.
Matt Smith
analystFor my follow-up, I'd like to discuss the IQOS IMS growth that you mentioned. You saw solid growth during Q1. My recollection is that it exceeded 9%. However, looking back at Q4, the figure stood at roughly 13%, and now you anticipate IMS growth and IQOS IMS growth picking up speed again throughout the rest of 2025. So could you discuss a few of the fundamental drivers behind that reacceleration in IMS growth over the remainder of 2025? That's all from me.
Emmanuel Babeau
executiveRight. So 9.4% did indeed match what we had anticipated. Those expectations are — and Europe came in under the average. So turbulence keeps arising from how the flavor ban has been implemented across Europe. Our view is that the effect will be smaller during H2 as annualization takes hold. Consequently, we anticipate an acceleration in H2, as I said, for IMS growth during the second half across Europe. Beyond that, we're looking at that 10% to 12% adjusted IMS growth for the full year; thus we foresee an overall continuation of solid double-digit growth. Q4 proved quite strong following several quarters that had been softer during the prior year, which created some phasing across the year; yet following this Q1, which matched expectations, we anticipate continued very healthy growth across Europe and in Japan. And I spent some time during my remarks addressing the other market where we're likewise seeing quite promising growth across a number of markets.
Eric Serotta
analystWhen it comes to the guidance for the whole year, you did lift shipment volumes. And clearly, that product carries a very high margin. You left constant currency EPS unchanged. In the first half, you turned in some extremely strong margin expansion. Are there particular offsets you could identify that led you to restate the guidance instead of letting a bit more flow through into the full year? Or is it more that we're only at the start of the year, and there's clearly a great deal of macro and geopolitical uncertainty?
Emmanuel Babeau
executiveThanks for that question, Eric. So it's true that we were aiming at a year of really powerful growth and performance. And Q1, I'd say, is signaling that we're firmly on track for a year of strong growth. So what we're doing is confirming our expectation of a year of very strong growth right across the board at PMI. What Q1 has shown us really does give confidence that this strong year will be delivered. For ZYN in the U.S., we're lifting the guidance volume by an average of 20 million cans. So yes, it's a highly profitable brand, though not to a degree that would dramatically alter this year's outlook. So I'd put it this way: that feeds into the various scenarios we work with when providing the year's guidance. And clearly, with just one quarter behind us and in this volatile, uncertain environment, we of course need to stay cautious and recognize this is only the year's beginning. And we're glad to reaffirm the guidance. Once again, I believe Q1 demonstrates that we're firmly on track to deliver a very good 2025.
Eric Serotta
analystThen one more quick thing. When it comes to ZYN, how do you folks think about what that unconstrained offtake growth would theoretically look like? Clearly, it isn't something you can see directly — you might make an estimate — but how do you think about the way it develops? Where it stands right now, and how it changes as you move into the back half and into next year, when the business is clearly much bigger than it was at the time you acquired it. So a precise answer really isn't possible, but any insight would help.
Emmanuel Babeau
executiveEric, honestly, we don't know what unconstrained demand is, of course, since demand remains constrained. So an answer isn't something I can give. What I can tell you is that as we lift the limitation and the out-of-stock situation, we certainly anticipate an acceleration in consumer offtake. And we're quite encouraged by how nicely dynamic the category is, which demonstrates the appeal and the attraction for the consumer, along with all those legal age nicotine users who are finding the category and seeing the benefit. So an acceleration is what we expect. Gradually, we'll return to normal life, because it's true that we've said we had very limited commercial marketing activities. So our effort was to serve the existing ZYN consumer. And we knew that attempting to bring in new consumers wasn't reasonable at a point when we couldn't serve and supply them. So clearly, there's another leg of growth there in the quarters ahead. And I suppose that's certainly something tied to unconstrained demand. But honestly, speculating on what that unconstrained demand will be isn't something I want to do. A gradual acceleration of consumer uptake for ZYN is what we expect in the months ahead.
Eric Serotta
analystUnderstood. Then just a single brief final question. You brought up the Nielsen figures with regard to ZYN. When you examine certain nontrack channels — where your visibility would be superior to ours — are you noticing any differing or diverging patterns?
Emmanuel Babeau
executiveWell, I certainly wouldn't claim Nielsen isn't a worthwhile data source. Naturally, though, it covers 3,000 sales points versus what is likely nearer to 200,000. And in an out of stock scenario, some distortion can emerge around how consumer offtake is perceived. So I can't state whether that 15% — we recognize, of course, that it's an estimate. What I did report was the MSA. That is, the quite favorable acceleration late in March in sales moving from wholesaler and distributor through to retailers. That's the additional point available to us. Beyond that, though, we possess no other reliable data, I'd say, that could be shared with you. We can convey to the market the extremely strong underlying demand for ZYN; that part is unmistakable. And I likewise pointed out the consumer offtake; meaning what Nielsen measured during last year's first quarter, which was probably considerably above the 130 million can figure we reported for that quarter — the first quarter of 2024. So that's the foundation upon which the 15% ought to be applied — the 15% serves to give you a sense of consumer offtake as it stands today.
Faham Baig
analystI've got a few questions too. To start, let's go back to ZYN's growth and the offtake. Can you share what the MSA data shows as the growth rate for ZYN, and how that actually stacks up against the 30% to 35% growth you mentioned for the category? My second question stays with the U.S. and IQOS. I'd like to hear your take on the recent CTP developments and whether that affects when ILUMA launches in the market, or if it doesn't affect the launch timing, that would be useful to know. And the last one is really administrative. Net interest guidance for the year would be helpful.
Emmanuel Babeau
executiveSorry, I missed that last question, Farhan.
Faham Baig
analystCould you give us the net interest cost guidance for the year, please?
Emmanuel Babeau
executiveSure. Let me take your question in the order you asked. On growth — I believe we mentioned that the share was near 66% on MSA in March, and it's likely a growth of about 30%, though I'd treat that with some caution. I'm not certain I have very precise data; but it's clear the MSA was decelerating as more products arrived. That's one point. Regarding the new situation at the CTP and what it means for IQOS, no, it's too early to say. So there's nothing to report; and I don't know what will happen. I think we're still hoping for an efficient process to be put in place and for the FDA to comply with the mandate, which was to give an answer after 6 months. But I have nothing new to report on this situation at this stage. And on the net interest for the year, I think you have a performance in Q1. I don't have that said, nothing specific to tell you for the full year. We're not providing any additional data for the full year. But of course, we started the year well. Nevertheless, with some positive incoming from mark-to-market on some of our hedging.
James Bushnell
executiveAppreciate it; that brings today's call to a close. Just so you know, the transcript of this call is available on our site for anyone who might have run into audio problems partway through the webcast. Many thanks for being with us. Should anything else come to mind, feel free to reach out to the Investor Relations team. Thanks once more, and enjoy the rest of your day.
Emmanuel Babeau
executiveThank you all, and speak to you soon. Thank you.
Operator
operatorThis concludes today's conference call. Thank you for participating, and you may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.